SCHEMBL2529528

SCHEMBL2529528

C=CCN(C(=O)OCc1ccccc1)c1cc(C(=O)O)cc(N(C)S(=O)(=O)CCC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TGM2 P21980 2/20 0.35
F13A1 P00488 1/20 0.35
TGM1 P22735 1/20 0.35
TSHR P16473 1/20 0.35
CCR5 P51681 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 1/20 0.33
F2 P00734 1/20 0.33
ELANE P08246 1/20 0.33
CTSG P08311 1/20 0.33
SIGMAR1 Q99720 2/20 0.32
HTR1A P08908 1/20 0.32
CHRM5 P08912 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
DRD1 P21728 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2527725 0.91 MAPT (0.40) ALDH1A1MAPTHPGDTGM2F13A1
SCHEMBL4874179 0.82 ALDH1A1 (0.42) ALDH1A1MAPTHPGDTGM2F13A1
SCHEMBL2530897 0.81 ALDH1A1 (0.43) ALDH1A1MAPTHPGDTGM2F13A1
SCHEMBL2526958 0.81 ALDH1A1 (0.41) ALDH1A1MAPTHPGDTSHRMEN1
SCHEMBL2526914 0.79 TSHR (0.41) ALDH1A1MAPTHPGDTGM2F13A1
SCHEMBL2528124 0.79 TSHR (0.49) ALDH1A1MAPTHPGDTSHRMEN1
SCHEMBL4872653 0.77 ALDH1A1 (0.40) ALDH1A1MAPTHPGDTSHRMEN1
SCHEMBL4877059 0.76 MEN1 (0.39) ALDH1A1MAPTHPGDTSHRMEN1
SCHEMBL2532574 0.76 MEN1 (0.45) ALDH1A1MAPTHPGDTSHRMEN1
SCHEMBL4874436 0.75 CCR5 (0.41) ALDH1A1MAPTCCR5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039455-B2 Macrocyclic compounds useful as BACE inhibitors NOVARTIS AG (CH) 2011-10-18 US disclosed
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-1968954-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2008-09-17 EP disclosed
WO-2007077004-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS SLC10A2, SLC10A1, ASAH2 ALDH1A1 2955/4885MAPT 2771/4885HPGD 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.